FDA consults on co-development of unmarketed drugs for use in combination
This article was originally published in SRA
The US Food and Drug Administration has issued for consultation draft guidance to help pharmaceutical companies in the co-development of two or more previously unmarketed drugs to be used in combination to treat a disease or a condition1-3.
You may also be interested in...
Stay current on regulatory guidelines from around the world with Medtech Insight's Guidance Tracker. Sixty-nine guidance documents have been posted on the tracker since its last update.
A UK regulator with the MHRA is concerned that bioanalytical laboratories are not being given enough time to do their job properly by drug companies under pressure to ensure their clinical trials remain on schedule.
The UK regulator is expecting a rise in amendments and deviations to ongoing clinical investigations of medical devices due to the COVID-19 pandemic and has issued advice on how companies should manage these.